United Kingdom· GB-APID-9524611000001103
Fabrazyme 35mg powder for concentrate for solution for infusion vials
A agalsidase beta product containing agalsidase beta, registered in United Kingdom by Sanofi. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Agalsidase beta is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB04 (agalsidase beta), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Agalsidase beta · ATC A16AB04
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of agalsidase beta costs, country by country.
Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Agalsidase beta · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$638.56
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Agalsidase beta
- Manufacturer
- Sanofi
- Country
- United Kingdom (GB)
- ATC code
- A16AB04
- ATC class
- Agalsidase beta
- Defined daily dose
- 5 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5030045000173
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
4 interactions on record for agalsidase beta.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Agalsidase beta · interactions on record
4 records
- 3 severe
- 1 moderate
Most severe, free to view
- AmiodaroneC01BD01severe
- GentamicinJ01GB03severe
- ChloroquineP01BA01severe
- MigalastatA16AX14moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Agalsidase beta in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaFABRAZYMESanofi B.V., Amsterdam
- SpainFABRAZYME 35 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONSanofi B.V.
- BelgiumFabrazyme 35 mgSanofi
- IrelandFabrazyme 35 mg powder for concentrate for solution for infusionSanofi B.V.
- NorwayFabrazymeSanofi B.V.
- PolandFabrazymeSanofi B.V.
- FinlandFabrazymeSanofi B.V.
- Japanアガルシダーゼベータ（遺伝子組換え）サノフィ
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Fabrazyme
- Liechtenstein · Fabrazyme
- Norway · Fabrazyme
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0adc2fd3-18bb-450b-8adf-20c1dbdbf4bb GET /v1/drugs/0adc2fd3-18bb-450b-8adf-20c1dbdbf4bb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "9524611000001103",
"desc": "Fabrazyme 35mg powder for concentrate for solution for infusion vials (Sanofi)",
"form": "Powder for solution for infusion",
"vpid": "41758011000001108",
"source": "dmd",
"vtm_id": "774445000",
"strength": "35 mg",
"substance": "Agalsidase beta",
"ingredient": "Agalsidase beta",
"supplier_code": "9190711000001101"
}See everything about agalsidase beta.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.